SCHEMBL762909

SCHEMBL762909

CC(C)(C)OC(=O)N1CC(=O)c2c[nH]c3cccc(c23)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 3/20 0.47
DDB1 Q16531 2/20 0.47
MAPK1 P28482 1/20 0.46
NAMPT P43490 3/20 0.40
ESR2 Q92731 1/20 0.39
KDM4E B2RXH2 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAPT P10636 2/20 0.39
USP2 O75604 1/20 0.39
RECQL P46063 1/20 0.39
PLEC Q15149 1/20 0.39
NR1H2 P55055 2/20 0.38
PARP1 P09874 2/20 0.38
TNKS2 Q9H2K2 1/20 0.38
PARP2 Q9UGN5 1/20 0.38
HDAC1 Q13547 1/20 0.37
BRD4 O60885 1/20 0.37
CREBBP Q92793 1/20 0.37
ALDH1A1 P00352 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL741195 0.81 PARP1 (0.41) KDM4EMEN1KMT2AMAPTUSP2
SCHEMBL741883 0.80 ESR2 (0.53) CRBNDDB1MAPK1NAMPTESR2
SCHEMBL17369314 0.79 MAPK1 (0.54) CRBNDDB1MAPK1NAMPTESR2
SCHEMBL29813840 0.79 MAPK1 (0.54) CRBNDDB1MAPK1NAMPTESR2
SCHEMBL16353839 0.78 ESR2 (0.53) CRBNDDB1MAPK1NAMPTESR2
SCHEMBL29676965 0.73 MAPK1 (0.64) CRBNDDB1MAPK1NAMPTESR2
SCHEMBL5183098 0.73 MAPK1 (0.64) CRBNDDB1MAPK1NAMPTESR2
SCHEMBL17699719 0.72 MAPK1 (0.47) CRBNDDB1MAPK1NAMPTESR2
SCHEMBL29782439 0.72 MAPK1 (0.47) CRBNDDB1MAPK1NAMPTESR2
SCHEMBL30812438 0.72 MAPK1 (0.47) CRBNDDB1MAPK1NAMPTESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138333-B2 Sulfonyl-indole derivatives PROXIMAGEN LIMITED (GB) 2012-03-20 US disclosed
US-8138333-B2 Sulfonyl-indole derivatives PROXIMAGEN LIMITED (GB) 2012-03-20 US disclosed
US-20080293694-A1 New compounds BIOVITRUM AB (PUBL.) (SE) 2008-11-27 US disclosed
US-20080293694-A1 New compounds BIOVITRUM AB (PUBL.) (SE) 2008-11-27 US disclosed
WO-2008110598-A1 TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY BIOVITRUM AB (PUBL) (SE) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293694-A1 New compounds HTR6, HTR1A, HTR1B CRBN 3014/4885DDB1 4733/4885MAPK1 1974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.